Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 185Neoplasms 11Prostate Adenocarcinoma 3Neoplasm Metastasis 3Adenocarcinoma 2Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Recurrence 1Prostatic Diseases 1Primary Dysautonomias 1PSA Level Greater Than Two 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Lymphatic Metastasis 1Lower Urinary Tract Symptoms 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Carcinoma 1Advanced Prostate Cancer 1Advanced Prostate Adenocarcinoma 1

Interventions

apalutamide 1abiraterone 1Radiosurgery 1Leuprolide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Newly Diagnosed Oligometastatic Prostate Cancer × Leuprolide × Genitourinary × Clear all
NCT03298087 2025-08-01

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

VA Office of Research and Development

Phase 2 Completed
28 enrolled 10 charts
Genitourinary

Newly Diagnosed Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡